Loading
IH
IMAC Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Ruiz Jorge, was filed 18 Mar 2025.
IMAC Holdings, Inc.: what insiders have been doing
Every trade that managers of IMAC Holdings, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Nothing new has been filed by managers of IMAC Holdings, Inc. in twelve months, the latest record being from 18 March 2025.
Over the whole record (from 2019), the tally stands at 15 purchases and 8 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
67
Thresholds
n/a
Buy Volume
€551,320
15 ops. · all time
Sell Volume
€594,465
8 ops. · all time
Since the insiders bought
- -86.9%Entry US$0.43 · Close at T+365 US$0.06
- +91.2%Entry US$24.00 · Close at T+365 US$45.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$72.1k
Gross profit-US$233.2k-324% margin
EBITDA-US$5.5M-7607% margin
Net income-US$9M-12554.9% margin
Valuation
Beta2.00
Balance sheet & cash
Total debtUS$4.2M
Free Cash Flow-US$3.2M
Profitability & ownership
ROA-550.7%
% insiders1.5%
% institutions0.0%
Last declaration on 18 March 2025
Declarations67 total
1 shares@ US$2.690.0% of flowCommon stockSEC:0002060450-25-000007:0
Canonical exit: 4 Jul 2024 (T+90)
5,000 shares@ US$3.0098.4% of flowCommon stockSEC:0002060450-25-000006:0
16,487 shares@ US$2.420.0% of flowCommon stockSEC:0002060450-25-000003:1
200 shares@ US$2.44Common stockSEC:0002060450-25-000004:1
500 shares@ US$2.45Common stockSEC:0002060450-25-000004:2
1,000 shares@ US$2.45Common stockSEC:0002060450-25-000004:3
356 shares@ US$2.44Common stockSEC:0002060450-25-000004:4
164,872 shares@ US$3.579797.5% of flowCommon stockSEC:0002060450-25-000003:0
Canonical exit: 20 Jun 2024 (T+90)
100 shares@ US$2.4151.6% of flowCommon stockSEC:0002060450-25-000004:0
3,333 sharesCommon Stock, no par valueSEC:0001493152-25-000073:0
3,333 sharesCommon Stock, no par valueSEC:0001493152-25-000071:0
3,333 sharesCommon Stock, no par valueSEC:0001493152-25-000070:0
3,333 sharesCommon Stock, no par valueSEC:0001493152-25-000074:0
3,333 sharesCommon Stock, no par valueSEC:0001493152-25-000072:0
3,333 sharesCommon StockSEC:0000921895-23-002803:0
3,333 sharesCommon StockSEC:0000921895-23-002801:0
3,333 sharesCommon StockSEC:0000921895-23-002802:0
37,000 shares@ US$0.311Common StockSEC:0001493152-22-029221:1
100,000 shares0Common StockSEC:0001493152-22-029220:0
100,000 shares0Common StockSEC:0001493152-22-029221:0
100,000 shares0Common StockSEC:0001493152-22-029219:0
9,375 sharesCommon StockSEC:0001493152-22-015056:0
37,500 sharesCommon StockSEC:0001493152-22-015054:0
100,000 shares0Common StockSEC:0001493152-22-005275:0
50,000 sharesCommon StockSEC:0001493152-22-000613:0
25 of 67 declarations
About IMAC Holdings, Inc.
IMAC Holdings, Inc. (ticker: BACK) is a U.S.-listed company on the NASDAQ market in the United States, historically positioned in specialized healthcare services with an emphasis on orthopedic therapies, rehabilitation, and minimally invasive procedures. The company originated as IMAC Holdings, LLC, a Kentucky limited liability company, and was converted into IMAC Holdings, Inc., a Delaware corporation, effective June 1, 2018. Its principal executive office is in Franklin, Tennessee. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1729944/000149315223010385/form10-k.htm?utm_source=openai))
From a business-model perspective, the SEC filings show that IMAC has operated as a holding company for several lines of activity: IMAC Regeneration Centers, BackSpace retail/clinic locations, and an Investigational New Drug division. Historically, the company focused on conservative, non-invasive or minimally invasive treatments for back pain, knee pain, joint pain, ligament and tendon damage, and other soft-tissue conditions. Its disclosures also note partnerships with well-known sports figures, reflecting an effort to build brand awareness and credibility in sports medicine and performance-oriented care. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1729944/000149315219005467/form10-k.htm?utm_source=openai))
Read moreShow less
That said, the recent operating history indicates a major strategic reset. SEC documents state that in 2023 the company decided to discontinue business activities related to underperforming clinic locations and BackSpace retail stores. In other words, IMAC has been shrinking and simplifying its footprint rather than expanding it. For investors, that is an important signal: the story is no longer about rapid clinic rollout, but about restructuring, liquidity management, and preserving optionality. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1729944/000149315224019793/form10-q.htm?utm_source=openai))
Competitive positioning is best viewed in the context of a highly fragmented U.S. healthcare market. IMAC’s historic peers would include independent orthopedic practices, outpatient rehabilitation providers, sports medicine clinics, and ambulatory care groups. The company’s differentiated pitch was a non-opioid, function-focused treatment model. However, its small scale, repeated restructuring, and financial pressure mean it should be viewed more as a speculative microcap than as a stable, scaled healthcare platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1729944/000149315222009946/form10-k.htm?utm_source=openai))
Recent developments reinforce this conclusion. In 2025 and 2026, IMAC entered into multiple debt-related transactions, including promissory notes and secured financing arrangements, reflecting ongoing liquidity needs. SEC filings also reference restructuring steps involving secured notes and creditor agreements. For French, Belgian, and Swiss investors, BACK therefore requires a cautious reading: it is a Nasdaq-listed U.S. healthcare name with very limited operating visibility, elevated financial risk, and a heavy dependence on SEC-filed disclosures for any meaningful assessment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001729944/000149315225029639/form8-k.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
